Zealand’s presentation at the Jefferies 2013 Global Healthcare Conference to be webcast

        Print
| Source: Zealand Pharma A/S
multilang-release

Copenhagen, 2013-05-31 12:08 CEST (GLOBE NEWSWIRE) -- Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”), a Danish biotechnology company dedicated to the discovery and development of novel peptide drugs, is scheduled to make a presentation at the Jefferies 2013 Global Healthcare Conference taking place from June 3 – 6, 2013 at The Grand Hyatt in New York.

Zealand is scheduled to present on Monday  June 3, 2013 at 3:30pm ET, and the presentation given by David H. Solomon, President and CEO of Zealand will be webcast live and can be accessed via the following link:

 

http://wsw.com/webcast/jeff77/zeal/

 

Listeners are encouraged to visit the site at least 10 minutes prior to the scheduled presentation to register, download and install any necessary audio software.

 

The webcast can also be accessed from the Investor section of Zealand’s website, www.zealandpharma.com, where a replay can also be accessed for 90 days following the presentation. 

 

As announced on 21 May (Investor News 04/2013), no new financial or other material new information relating to Zealand will be disclosed in the webcast at the above conference.

 

***

 

 

 

For further information, please contact:

 

Hanne Leth Hillman, Vice President, Head of Investor Relations & Corporate Communications

Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

 

About ZealandZealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) is a biotechnology company based in Copenhagen, Denmark. Zealand specializes in the discovery, optimization and development of novel peptide drugs and has a broad and mature pipeline of drug candidates identified through its own drug discovery activities. The company’s focus lies in the field of diabetes/metabolic diseases, and its lead drug invention is lixisenatide, a once-daily GLP-1 agonist, which is licensed to Sanofi for the treatment of Type 2 diabetes. Lixisenatide is approved and launched (March 2013) in Europe under the name of Lyxumia®, and under regulatory review in a large number of other countries globally, including in the US (NDA filed in Dec 2012) and Japan (NDA filed in June 2012).

 

Zealand has a partnering strategy for the development and commercialization of its products and in addition to the collaboration with Sanofi in Type 2 diabetes, the company has partnerships with Boehringer Ingelheim in diabetes/obesity, Helsinn Healthcare in chemotherapy induced diarrhea and AbbVie in acute kidney injury.  For further information: www.zealandpharma.com.                   

                                                                               

Follow Zealand on Twitter: @ZealandPharma